From: The protective role of statins in COVID-19 patients: a retrospective observational study
Total N = 3252 | Unmatched | Matched | ||||
---|---|---|---|---|---|---|
Statin use 1048 (32.2%) | No statin use 2204 (67.7%) | p value | Statin use (n = 768) | No statin use (n = 768) | p value | |
Demographics | ||||||
 Age (years) | 63 (55–79) | 59 (45–77) | < 0.001 | 62 (54–76) | 64 (55–77) | 0.16 |
 Gender |  |  | 0.05 |  |  | 1.0 |
  Male | 550 (52.4%) | 1266 (57.4%) |  | 422 (54.9%) | 446 (58.0%) |  |
  Female | 498 (47.5%) | 938 (42.5%) |  | 346 (45.0%) | 322 (41.9%) |  |
 BMI (kg/m2) | 28.2 (24.1–31.8) | 27.8(24.4–32.0) | 0.24 | 28.3 (24.6–32.4) | 27.2 (23.8–31.8) | 0.62 |
 Comorbidities | ||||||
  HTN | 786 (75.0%) | 1280 (58.0%) | < 0.001 | 484 (63.0%) | 546 (71.0%) | 0.45 |
  DM | 656 (62.5%) | 890 (40.3%) | < 0.001 | 424 (55.2%) | 448 (58.3%) | 0.54 |
  CAD | 498 (47.5%) | 818 (37.1%) | < 0.001 | 124 (16.1%) | 116 (15.1%) | 0.74 |
  CLD | 410 (39.1%) | 536 (24.3%) | < 0.001 | 186 (24.2%) | 192 (25.0%) | 0.45 |
  CKD | 390 (37.2%) | 352 (15.9%) | < 0.01 | 168 (21.8%) | 160 (20.8%) | 0.75 |
  CVA | 116 (11%) | 66 (2.9%) | < 0.01 | 70 (9.1%) | 66 (8.5%) | 0.86 |
  Heart failure | 440 (41.9%) | 728 (33.0%) | 0.96 | 128 (16.6%) | 124 (16.1%) | 0.88 |
  Liver disease | 72 (6.8%) | 88 (3.9%) | 0.98 | 72 (9.3%) | 56 (7.2%) | 0.70 |
Clinical features | ||||||
 Fever (oc) | 37.45 ± 1.16 | 37.41 ± 1.04 | 0.787 | 37.31 ± 1.09 | 37.22 ± 1.04 | 0.60 |
 Dyspnoea n(%) | 1004 (95.8%) | 1720 (78.0%) | < 0.01 | 640 (83.3%) | 624 (81.2%) | 0.88 |
 Cough n (%) | 978 (93.3%) | 1802 (81.7%) | < 0.01 | 606 (78.9%) | 594 (77.3%) | 0.87 |
 Chest pain n(%) | 52 (4.9%) | 108 (4.9%) | < 0.001 | 70 (9.1%) | 78 (10.1%) | 0.88 |
 Fatigue n (%) | 972 (92.7%) | 1686 (76.4%) | < 0.01 | 592 (77.0%) | 602 (78.3%) | 0.86 |
 O2 saturation (Spo2 ≤ 93%) | 314 (29.9%) | 1328 (30.1%) | < 0.001 | 228 (29.6%) | 216 (28.1%) | 0.88 |